# MindMaze Therapeutics Holding SA

> MindMaze Therapeutics Holding SA (SIX:MMTX, OTCQB:MMTZF) announcements published on FAQSIR. AI-generated content. Paid-for issuer communication. Not investment advice.

canonical: https://faqsir.com/company/mindmaze-therapeutics-holding-sa
generated_at: 2026-10-16T20:02:22+00:00

## Company

- Name: MindMaze Therapeutics Holding SA
- Listings: SIX:MMTX, OTCQB:MMTZF
- Also known as: MindMaze Therapeutics, MindMaze
- Website: https://mindmazetherapeutics.com

## Disclosure

- AI-generated content: This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.
- Unpaid evaluation: The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.
- Not investment advice: This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.
- Grounding: Content is generated from the company's published announcements.
- Disclosure version: 2026.09.3

## Endpoints

- [Company hub](https://faqsir.com/company/mindmaze-therapeutics-holding-sa): the MindMaze Therapeutics Holding SA announcements listed below, as a page
- [Latest announcement](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/latest): redirects to the newest release, or to the hub when there is no recent one
- [Atom feed](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/feed): the latest 50 releases, as Atom
- [JSON feed](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/feed.json): the latest 50 releases, as JSON Feed 1.1
- [Site-wide llms.txt](https://faqsir.com/llms.txt): what this site publishes beyond this issuer

## Releases

Every announcement this hub lists: 19 announcements, newest first. Each URL is that release's canonical URL.

- 2026-10-14 — [MindMaze Reports Home-Rehabilitation Findings as MindMotion Lite Is Expected by Year-End 2026](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-reports-home-rehabilitation-findings-as-mindmotion-lite-is-expected-by-year-end-2026): MindMaze Therapeutics reported increased training exposure and functional improvements in a retrospective home-based rehabilitation programme conducted with Vibra Healthcare.
- 2026-09-17 — [MindMaze Therapeutics announces planned MindMotion Lite launch by end of 2026](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-announces-planned-mindmotion-lite-launch-by-end-of-2026): MindMaze Therapeutics plans to launch MindMotion Lite by the end of 2026, bringing its MindMotion neurorehabilitation activities to a tablet-based format for home use.
- 2026-09-01 — [MindMaze Therapeutics Announces Upcoming Investor and Industry Conference Appearances](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-announces-upcoming-investor-and-industry-conference-appearances): MindMaze Therapeutics has announced plans to participate in upcoming investor and industry conferences in the United States and Europe, with management available for one-on-one meetings.
- 2026-08-27 — [MindMaze Therapeutics Reports H1 2026 Revenue of CHF 0.5 Million and Corporate Update](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-reports-h1-2026-revenue-of-chf-05-million-and-corporate-update): MindMaze Therapeutics announced its 2026 half-year report, reporting CHF 0.5 million in revenue and a CHF 6.9 million net loss for the six months ended June 30, 2026.
- 2026-08-12 — [MindMaze Therapeutics appoints John Krakauer as strategic advisor](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-appoints-john-krakauer-as-strategic-advisor): MindMaze Therapeutics has appointed Dr. John Krakauer as a strategic advisor, citing his role in the development of its MindPod rehabilitation system and the scientific foundations of its platform.
- 2026-08-10 — [MindMaze Completes Organisational Simplification and Updates Neuro.io Financing](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-completes-organisational-simplification-and-updates-neuroio-financing): MindMaze Therapeutics has completed its organisational simplification and revised the schedule for the remaining CHF 4.0 million tranche of its Neuro.io financing.
- 2026-07-01 — [MindMaze Reports First SwissNeuroRehab Enrolments and Launch of French Stroke Study](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-reports-first-swissneurorehab-enrolments-and-launch-of-french-stroke-study): MindMaze Therapeutics has reported first-patient enrolment in the SwissNeuroRehab HDHI study and launched REACT-AVC in France as part of its European at-home reimbursement strategy.
- 2026-06-25 — [MindMaze Therapeutics reports AGM outcome as conditional capital proposal fails to secure majority](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-reports-agm-outcome-as-conditional-capital-proposal-fails-to-secure-majority): MindMaze Therapeutics Holding SA says shareholders approved its Annual General Meeting proposals except a proposed increase in conditional share capital. Five directors, including Brad Hollinger and Z...
- 2026-06-03 — [MindMaze Therapeutics Publishes Invitation for 2026 Annual General Meeting](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-publishes-invitation-for-2026-annual-general-meeting): MindMaze Therapeutics will hold its 2026 Annual General Meeting on June 25, 2026, in Geneva, with shareholders set to vote on board appointments, financial statements, compensation and conditional sha...
- 2026-06-02 — [MindMaze Announces RLF-OD032 Rights Sale and Planned Organisational Simplification](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-announces-rlf-od032-rights-sale-and-planned-organisational-simplification): MindMaze Therapeutics announced the sale of rights to its RLF-OD032 phenylketonuria programme and plans to dispose of most remaining non-neurology legacy operations.
- 2026-05-26 — [MindMaze Announces CHF 8.0 Million Equity Financing With Neuro.io](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-announces-chf-80-million-equity-financing-with-neuroio): MindMaze Therapeutics has entered into a definitive agreement with Neuro.io for a CHF 8.0 million equity financing, while the companies explore broader strategic opportunities.
- 2026-05-12 — [MindMaze Therapeutics and Vibra Healthcare Sign U.S. Neurorehabilitation Partnership](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-and-vibra-healthcare-sign-us-neurorehabilitation-partnership): MindMaze Therapeutics and Vibra Healthcare have signed a definitive channel partnership agreement covering the expansion of MindMaze’s digital neurotherapeutics platform across U.S. health systems.
- 2026-04-30 — [MindMaze and Vibra Sign Term Sheet for Planned U.S. Go-to-Market Partnership](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-and-vibra-sign-term-sheet-for-planned-us-go-to-market-partnership): MindMaze Therapeutics and Vibra Healthcare have announced a planned U.S. go-to-market collaboration, with initial market-development work already underway and a definitive agreement still pending.
- 2026-04-15 — [MindMaze Therapeutics Publishes 2025 Annual Report and Reports CHF 9.9 Million Net Loss](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-publishes-2025-annual-report-and-reports-chf-99-million-net-loss): MindMaze Therapeutics has published its 2025 Annual Report, outlining clinical evidence, U.S. expansion plans, leadership changes and financial results.
- 2026-03-31 — [MindMaze and Vibra report neurorehabilitation results from two-year programme](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-and-vibra-report-neurorehabilitation-results-from-two-year-programme): MindMaze Therapeutics and Vibra Healthcare reported real-world evidence from a two-year programme using technology-enabled supplemental therapy for stroke patients in inpatient rehabilitation.
- 2026-03-12 — [MindMaze Therapeutics Names Zach Henderson CEO as Company Targets U.S. Expansion](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-names-zach-henderson-ceo-as-company-targets-us-expansion): MindMaze Therapeutics has appointed Zach Henderson as Chief Executive Officer as the company works to expand its U.S. presence and adoption of its FDA-cleared platform.
- 2026-03-03 — [MindMaze Therapeutics outlines post-listing plans and publishes March 2026 presentation](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-outlines-post-listing-plans-and-publishes-march-2026-presentation): MindMaze Therapeutics provided a post-listing corporate update covering U.S. commercial discussions, European studies, organisational integration and governance changes.
- 2025-12-23 — [MindMaze Therapeutics outlines reimbursement strategy across US, Switzerland and UK](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-outlines-reimbursement-strategy-across-us-switzerland-and-uk): MindMaze Therapeutics has detailed a reimbursement strategy combining US deployment, Swiss clinical evidence generation and UK engagement with NICE evaluation frameworks.
- 2025-12-15 — [MindMaze Therapeutics completes NeuroX business combination](https://faqsir.com/company/mindmaze-therapeutics-holding-sa/mindmaze-therapeutics-completes-neurox-business-combination): MindMaze Therapeutics Holding SA has completed its business combination with NeuroX Group SA following shareholder approval in November 2025.